January 29, 2018
IJMS: Induction of Pro-Apoptotic Endoplasmic Reticulum Stress in Multiple Myeloma Cells by NEO214, Perillyl
Alcohol Conjugated to Rolipram
July 27, 2017
ABTA: Patients, caregivers hear about advances in brain tumor treatments
The Keck School of Medicine of USC recently hosted a symposium for the American Brain Tumor Association, called Partners in Treatment and Care, that was attended by dozens of patients, family members and caregivers from the Los Angeles area.
June 10, 2017
Brain Tumor Treatment Trends
Dr Thomas Chen presents at the American Brain Tumor Association Patient & Caregiver Meeting, June 10, 2017 at USC Keck School of Medicine.
Click Here: BROKEN YOUTUBE LINK
April 17, 2017
April 2017 – Cancer Letters
A perillyl alcohol-conjugated analog of 3-bromopyruvate without cellular uptake dependency on monocarboxylate transporter 1 and with activity in 3-BP-resistant tumor cells
May 01, 2017
NeOnc Technologies, Inc May 2017 Newsletter
I appreciate your interest in the work done by NeOnc Technologies, Inc. (NTI) and your continued trust. I want to update you on the progress of our activities in a number of areas.
Memorial Sloan Kettering Cancer Center
January 31, 2017
Noveome Biotherapeutics, Inc.
Data Demonstrating Anti-Inflammatory Activity of ST266 in a Preclinical Model of Optic Neuritis
May 13, 2016
May 2016: Press Release
NeOnc Technilogies announces initiation of Phase 1/2a clinical trial of NEO100 in recurrent Glioblastoma multiforme (GBM)
March 01, 2016
Intranasal Drug Delivery Bypasses the BloodBrain Barrier
December 01, 2015
December 2015: Newsletter
This is an exciting time for NeOnc TECHNOLOGIES INC. (NeOnc) as we get close to the launch of our Clinical Trial for NEO100. Agreements and protocols are being finalized with each of the six centers involved.
January 01, 2015
January 2015: Newsletter
Last year was an extremely productive and exciting year for NEONC TECHNOLOGIES INC. (Neonc). Many significant events occurred and milestones were achieved resulting in a great year for the Company and our Investors.
September 04, 2014
A novel Temozolomide analog, NEO212, with enhanced activity against MGMT-positive melanoma in vitro and in vivo
March 12, 2014
Molecular Cancer Therapeutics – 2014
NEO212, Temozolomide Conjugated to Perillyl Alcohol?
January 01, 2014
Molecular Cancer Therapeutics – March 2014
A Novel Temozolomide Perillyl Alcohol Conjugate Exhibits Superior Activity against Breast Cancer Cells in vitro and Intracranial Triple-Negative Tumor Growth in vivo?
December 01, 2013
Article in Anticancer Research
Long-term Outcome in Patients with Recurrent Malignant Glioma Treated with Perillyl Alcohol Inhalation
February 06, 2013
February 2013: Press Release
NEONC Technologies, Inc. (NTI), an early-stage biotechnology company developing new drugs using
intranasal brain delivery, today announced that the companys NEO100 compound will undergo extensive clinical testing for treatment of gliomas and other cancers of the central nervous system.
August 01, 2012
Molecular Cancer Therapeutics August 2012
Perillyl Alcohol (POH) For the Treatment of Temozolomide-Resistant Gliomas
March 01, 2010
March 2010: JCRCO
ORIGINAL PAPER: Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma
NeOnc on Brazilian TV